Johnson & Johnson EBIT 2012-2026 | JNJ
Johnson & Johnson annual and quarterly EBIT history from 2012 to 2026. EBIT can be defined as earnings before interest and taxes.
- Johnson & Johnson EBIT for the quarter ending March 31, 2026 was $5.947B, a 58.02% decline year-over-year.
- Johnson & Johnson EBIT for the twelve months ending March 31, 2026 was $26.388B, a 8.08% decline year-over-year.
- Johnson & Johnson 2025 annual EBIT was $34.608B, a 84.34% increase from 2024.
- Johnson & Johnson 2024 annual EBIT was $18.774B, a 9.82% increase from 2023.
- Johnson & Johnson 2023 annual EBIT was $17.095B, a 15.06% decline from 2022.
|
Johnson & Johnson Annual EBIT (Millions of US $) |
|
|---|---|
| 2025 | $34,608 |
| 2024 | $18,774 |
| 2023 | $17,095 |
| 2022 | $20,125 |
| 2021 | $19,414 |
| 2020 | $16,809 |
| 2019 | $18,003 |
| 2018 | $19,615 |
| 2017 | $18,992 |
| 2016 | $20,897 |
| 2015 | $19,876 |
| 2014 | $21,163 |
| 2013 | $16,027 |
| 2012 | $14,371 |
| 2011 | $13,023 |
|
Johnson & Johnson Quarterly EBIT (Millions of US $) |
|
|---|---|
| 2026-03-31 | $5,947 |
| 2025-12-31 | $5,417 |
| 2025-09-30 | $7,965 |
| 2025-06-30 | $7,059 |
| 2025-03-31 | $14,167 |
| 2024-12-31 | $4,305 |
| 2024-09-30 | $3,823 |
| 2024-06-30 | $6,413 |
| 2024-03-31 | $4,233 |
| 2023-12-31 | $5,340 |
| 2023-09-30 | $5,783 |
| 2023-06-30 | $6,849 |
| 2023-03-31 | $-877 |
| 2022-12-31 | $2,916 |
| 2022-09-30 | $5,373 |
| 2022-06-30 | $5,942 |
| 2022-03-31 | $5,894 |
| 2021-12-31 | $1,311 |
| 2021-09-30 | $3,882 |
| 2021-06-30 | $6,714 |
| 2021-03-31 | $7,507 |
| 2020-12-31 | $1,747 |
| 2020-09-30 | $4,457 |
| 2020-06-30 | $4,004 |
| 2020-03-31 | $6,601 |
| 2019-12-31 | $4,384 |
| 2019-09-30 | $1,784 |
| 2019-06-30 | $7,212 |
| 2019-03-31 | $4,623 |
| 2018-12-31 | $3,568 |
| 2018-09-30 | $4,841 |
| 2018-06-30 | $5,352 |
| 2018-03-31 | $5,854 |
| 2017-12-31 | $2,919 |
| 2017-09-30 | $5,093 |
| 2017-06-30 | $5,080 |
| 2017-03-31 | $5,900 |
| 2016-12-31 | $4,608 |
| 2016-09-30 | $5,570 |
| 2016-06-30 | $5,182 |
| 2016-03-31 | $5,537 |
| 2015-12-31 | $3,971 |
| 2015-09-30 | $4,277 |
| 2015-06-30 | $5,896 |
| 2015-03-31 | $5,732 |
| 2014-12-31 | $2,859 |
| 2014-09-30 | $6,958 |
| 2014-06-30 | $5,768 |
| 2014-03-31 | $5,578 |
| 2013-12-31 | $2,902 |
| 2013-09-30 | $3,790 |
| 2013-06-30 | $4,928 |
| 2013-03-31 | $4,407 |
| 2012-12-31 | $3,225 |
| 2012-09-30 | $3,745 |
| 2012-06-30 | $2,192 |
| 2012-03-31 | $5,209 |
| 2011-12-31 | $536 |
| 2011-09-30 | $4,262 |
| 2011-06-30 | $3,569 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |